ASAP Act

This bill would require Medicare to cover early detection screening tests for Alzheimer's disease and related dementias starting January 1, 2028. It defines eligible tests as FDA-cleared genomic blood tests, blood product analyses, or equivalent medical imaging methods (like protein expression or whole genome sequencing) that detect pre-symptomatic or early-stage conditions. Medicare beneficiaries would receive this coverage without cost-sharing for these specific screenings. The bill amends Medicare coverage rules to explicitly include these tests under Section 1861(nnn) of the Social Security Act.